Event Registration
Upcoming JAX Event:
Heidelberg, Germany | Basel, Switzerland | Brussels, Belgium | Cambridge, England
Heidelberg, Germany
Basel, Switzerland
Brussels, Belgium
Cambridge, England
June 17 - 24, 2022
Summary
Presentation details of each location are listed below.
Heidelberg | Basel | Brussels | Cambridge
Heidelberg | Basel
Brussels | Cambridge
Events are complimentary.
No fees will be charged for registering.
|
Of Mice and Men - FcRn Biology and Its Implications in a Therapeutic Perspective Torleif Tollefsrud Gjølberg, Ph.D. Scientist, co-founder of Authera Oslo University Hospital |
Preclinical Assessment of Engineered Immunoglobulins in Immune Humanized Mice Brian Soper, Ph.D. Senior Scientific Engagement Manager The Jackson Laboratory |
Development of Novel Humanized Mouse Models for Biomedical Research Michael Brehm, Ph.D. Associate Professor, Diabetes Center of Excellence Program in Molecular Medicine University of Massachusetts Chan Medical School |
|
In Vivo CAR T Cell Generation in Humanized Mouse Models Naphang Ho Student Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines Germany |
Evaluation of Safety and Efficacy of Antibody-Based and CAR T Therapies in PBMC Humanized Mice James G. Keck, Ph.D. Senior Director, Innovation and Product Development The Jackson Laboratory |
Cytokine Release in the Context of T Cell Bispecific Antibody (TCB) Therapies: Biological Mechanisms and Mitigations Strategies Gabrielle Leclerq, Ph.D. Doctorate Scientist, Roche Pharma Research and Early Development Roche Innovation Center, Zurich |
|
Of Mice and Men - FcRn Biology and Its Implications in a Therapeutic Perspective Simone Mester, Ph.D. Scientist, co-founder of Authera Oslo University Hospital |
Preclinical Assessment of Engineered Immunoglobulins in Immune Humanized Mice Brian Soper, Ph.D. Senior Scientific Engagement Manager The Jackson Laboratory |
Development of Novel Humanized Mouse Models for Biomedical Research Michael Brehm, Ph.D. Associate Professor, Diabetes Center of Excellence Program in Molecular Medicine University of Massachusetts Chan Medical School |
|
Application of Humanized Mouse Models in Drug Discovery Johannes Sam, Ph.D. Leader In Vivo Models & Immunopharmacodynamics, Pharmacology, Roche Pharmaceutical Research & Early Development Roche Innovation Center Zurich |
When Is a Potent Antibody Against a Good Target Not a Drug? The Case for Early PK Adam Drake, Ph.D. Director In Vivo Pharmacology Ichnos Sciences Biotherapeutics, SA |
Evaluation of Safety and Efficacy of Antibody-Based and CAR T Therapies in PBMC Humanized Mice James G. Keck, Ph.D. Senior Director, Innovation and Product Development The Jackson Laboratory |
|
Validation of hFcRn Transgenic Mice as Powerful Models to Screen Innovative Fc-Engineered Monoclonal and Multi Specific Antibodies Delphine Valente, Ph.D. Head of Pharmacokinetics, Modeling and Simulation, DMPK France Sanofi |
Preclinical Assessment of Engineered Immunoglobulins in Immune Humanized Mice Brian Soper, Ph.D. Senior Scientific Engagement Manager The Jackson Laboratory |
Development of Novel Humanized Mouse Models for Biomedical Research Michael Brehm, Ph.D. Associate Professor, Diabetes Center of Excellence Program in Molecular Medicine University of Massachusetts Chan Medical School |
|
The Application of Humanized Mouse Models to Study LILRB-Mediated Regulation of Myeloid Cells Ali Roghanian, Ph.D. Lecturer (Assistant Professor) in Cancer Immunology & Immunotherapy University of Southampton |
Evaluation of Safety and Efficacy of Antibody-Based and CAR T Therapies in PBMC Humanized Mice James G Keck, Ph.D. Senior Director, Innovation and Product Development The Jackson Laboratory |
|
Of Mice and Men - FcRn Biology and Its Implications in a Therapeutic Perspective Jan Terje Andersen, Ph.D. Professor in Biomedical Innovation, co-founder of Authera Oslo University |
Preclinical Assessment of Engineered Immunoglobulins in Immune Humanized Mice Brian Soper, Ph.D. Senior Scientific Engagement Manager The Jackson Laboratory |
Development of Novel Humanized Mouse Models for Biomedical Research Michael Brehm, Ph.D. Associate Professor, Diabetes Center of Excellence Program in Molecular Medicine University of Massachusetts Chan Medical School |
|
Evaluation of Safety and Efficacy of Antibody-Based and CAR T Therapies in PBMC Humanized Mice James G. Keck, Ph.D. Senior Director, Innovation and Product Development The Jackson Laboratory |
Potency of PD-1+CTLA-4 Bispecific or Combination in a Humanized Mouse Model Richard Stebbings, Ph.D. Senior Director Oncology Safety Science AstraZeneca |
